Potential therapeutic and pharmacological strategies for SARS-CoV2

被引：0
|
作者：
Doaa A. Ghareeb
Samar R. Saleh
Mohammed S. Nofal
Mohamed M. Y. Kaddah
Salma. F. Hassan
Inas K. Seif
Sally A. El-Zahaby
Shaimaa M. Khedr
Marwa Y. Kenawy
Aliaa A. Masoud
Salma A. Soudi
Ahmed A. Sobhy
Jaillan G. Sery
Miral G. Abd El-Wahab
Alshimaa A. Abd Elmoneam
Abdulaziz Mohsen Al-mahallawi
Maha A. El-Demellawy
机构：
[1] Alexandria University,Biological Screening and Preclinical Trial Laboratory, Department of Biochemistry, Faculty of Science
[2] City of Scientific Research and Technological Applications (SRTA-City),Pharmaceutical and Fermentation Industries Development Centre (PFIDC)
[3] Pharos University in Alexandria,Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy
[4] City of Scientific Research and Technological Applications (SRTA-City),Fabrication Technology Department, Advanced Technology and New Materials Research Institute (ATNMRI)
[5] Alexandria University,Clinical Pharmacy Program, Faculty of Pharmacy
[6] Cairo University,Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy
[7] October University for Modern Sciences and Arts (MSA),Department of Pharmaceutics, Faculty of Pharmacy
[8] GEBRI,Medical Biotechnology Department
[9] SRTA-City,undefined
来源：
Journal of Pharmaceutical Investigation | 2021年 / 51卷
关键词：
COVID-19; Hydroxychloroquine; Indomethacin; Tocilizumab; Teicoplanin; Camostat;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：281 / 296
页数：15
相关论文
共 50 条
  • [31] Kidney implications of SARS-CoV2 infection in children
    Erica C. Bjornstad
    Michael E. Seifert
    Keia Sanderson
    Daniel I. Feig
    Pediatric Nephrology, 2022, 37 : 1453 - 1467
  • [32] Cardiac Damage After SARS-CoV2 Infection
    Bohlen, Ben
    Franzen, Damian
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (05)
  • [33] Pidotimod in Paucisymptomatic SARS-CoV2 Infected Patients
    Ucciferri, Claudio
    Barone, Mirko
    Vecchiet, Jacopo
    Falasca, Katia
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2020, 12
  • [34] Could Sars-Cov2 affect MS progression?
    Di Stadio, Arianna
    Romani, Luigina
    Bernitsas, Evanthia
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 46
  • [35] Immune checkpoint inhibitors and SARS-CoV2 infection
    Abdolmohammadi-Vahid, Samaneh
    Baradaran, Behzad
    Adcock, Ian M.
    Mortaz, Esmaeil
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 137
  • [36] SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies
    de Oliveira Campos, Daniel Melo
    Fulco, Umberto Laino
    Silva de Oliveira, Claudio Bruno
    Nobre Oliveira, Jonas Ivan
    JOURNAL OF EVIDENCE BASED MEDICINE, 2020, 13 (04) : 255 - 260
  • [37] A dissection of SARS-CoV2 with clinical implications (Review)
    Stancioiu, Felician
    Papadakis, Georgios Z.
    Kteniadakis, Stelios
    Izotov, Boris Nikovaevich
    Coleman, Michael D.
    Spandidos, Demetrios A.
    Tsatsakis, Aristidis
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2020, 46 (02) : 489 - 508
  • [38] Advances in the computational analysis of SARS-COV2 genome
    Machado, J. A. Tenreiro
    Rocha-Neves, J. M.
    Azevedo, Filipe
    Andrade, J. P.
    NONLINEAR DYNAMICS, 2021, 106 (02) : 1525 - 1555
  • [39] SARS-CoV2: Diagnostic tests available to the clinician
    Hadweh, Paul
    Orfanidou, Timoklia
    Tsiamita, Maria
    Timologos, Grigorios
    Papadopoulos, Theofanis
    HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2020, 23 : 8 - 14
  • [40] Investigating the relationship between occupation and SARS-CoV2
    Sarailoo, Mehdi
    Matin, Somaieh
    Vosoughi, Mehdi
    Dargahi, Abdollah
    Gholizadeh, Helia
    Damavandi, Marzie Rajabi
    Abbasi-Ghahramanloo, Abbas
    Kamran, Aziz
    WORK-A JOURNAL OF PREVENTION ASSESSMENT & REHABILITATION, 2021, 68 (01): : 27 - 32
12345